Decrease in high density lipoprotein cholesterol (HDL-C) levels following gemfibrozil therapy.
This report represents the continuation of our studies on the effects of gemfibrozil therapy on high density lipoprotein cholesterol levels. Previously, we reported that despite an impressive mean increase in high density lipoprotein cholesterol (20%), the response to 12 weeks of gemfibrozil therapy was highly variable. Accordingly, out of the 27 subjects studied, five actually had lower high density lipoprotein cholesterol at the conclusion of therapy compared to baseline values. The changes observed in plasma lipids, combined with correlational relationships suggest that the conversion of triglyceride rich lipoprotein components into high density lipoprotein may be impaired in those subjects that respond poorly or negatively to gemfibrozil therapy.
Department of Molecular Biology, University of North Texas Health Science Center, Fort Worth, USA.
A G
AG
Lacko
B J
BJ
Kudchodkar
W W
WW
Loney
M B
MB
Clearfield
S
S
Weis
D000328:Adult; D000368:Aged; D008076:Cholesterol, HDL / Q000097:blood*; D005260:Female; D015248:Gemfibrozil / Q000627:therapeutic use*; D006801:Humans; D015228:Hypertriglyceridemia / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D015248:Gemfibrozil